Centessa Pharmaceuticals Limited Stock News

BMO Capital has initiated coverage on Centessa Pharmaceuticals plc (NASDAQ: CNTA) with a price target of $19 (293% upside), and an Outperform rating. The analyst writes that ZF874 is a differenti

BOSTON and LONDON, March 23, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced today that Saurabh Saha, MD, PhD, Chief Executive Officer, will present at the Guggenheim Ge

Centessa Pharmaceuticals (NASDAQ:CNTA) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a report released on Thursday, Zacks.com reports. According to Zacks, Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) gapped up prior to trading on Tuesday . The stock had previously closed at $11.33, but opened at $11.82. Centessa Pharmaceuticals shares last traded at $12.03, with a volume of 1,219 shares changing hands. Separately, Zacks Investment Research raised Centessa Pharmaceuticals from a “hold” rating to a “buy” rating and set […]

Compagnie Lombard Odier SCmA bought a new stake in Centessa Pharmaceuticals Limited (NASDAQ:CNTA) in the 3rd quarter, Holdings Channel.com reports. The fund bought 2,750 shares of the companys stock, valued at approximately $46,000. Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) shares traded up 11% on Friday . The company traded as high as $12.20 and last traded at $12.20. 4,497 shares traded hands during trading, a decline of 98% from the average session volume of 200,208 shares. The stock had previously closed at $10.99. Separately, Zacks Investment Research lowered shares of []

Shares of Centessa Pharmaceuticals Limited (NASDAQ:CNTA) hit a new 52-week low on Wednesday . The company traded as low as $10.32 and last traded at $10.35, with a volume of 2183 shares trading hands. The stock had previously closed at $11.10. Separately, Zacks Investment Research downgraded Centessa Pharmaceuticals from a buy rating to a hold []

~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~ ~ All four subjects in the AL

~ Initiation of registrational Phase 3 ACTION clinical study with lixivaptan is an important milestone to bring this potential new treatment option to ADPKD patients ~

BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc ("Company") (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to disc…

BOSTON and LONDON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (“Company”) (Nasdaq: CNTA), a clinical-stage company leveraging its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, today announced that it has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 20, 2021.

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) was the target of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,970,000 shares, an increase of 26.3% from the October 31st total of 1,560,000 shares. Approximately 3.5% of the shares of the stock are sold short. Based on []

Centessa Pharmaceuticals Limited (NASDAQ:CNTA) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $10.50 and last traded at $11.56, with a volume of 386143 shares. The stock had previously closed at $11.60. Separately, Zacks Investment Research raised shares of Centessa Pharmaceuticals from a hold rating to a []